Tesamorelin may support certain aspects of longevity, regeneration, and healthy ageing by stimulating natural growth hormone (GH) and insulin-like growth factor-1 (IGF-1) pathways. Studies suggest it may improve visceral adipose tissue metabolism, support mitochondrial function, aid in maintaining lean muscle mass, and potentially benefit cognitive health. Although tesamorelin is FDA-approved solely for treating excess visceral adipose tissue associated with HIV, rather than as an anti-aging therapy, several clinical studies indicate that tesamorelin's activation of the GH–IGF-1 axis may positively impact biological processes related to ageing, including body composition, liver function, inflammation, cellular energy metabolism, and brain health [1–8]. For this reason, the topic of „Tesamorelin for Longevity” is gaining increasing traction within the longevity, healthy ageing, and metabolic optimisation communities.
Tesamorelin acts as a stabilised analogue of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release endogenous GH in a more physiological, pulsatile rhythm [1,2]. Increased GH levels then raise circulating IGF-1 levels, which are involved in tissue regeneration, protein synthesis, muscle maintenance, mitochondrial energy production, and metabolic regulation. Unlike direct recombinant growth hormone injections, tesamorelin activates the body's own hormonal pathways earlier in the hormonal axis, which may allow for more natural endocrine regulation to be maintained [1–3].
One of the most important areas related to ageing, studied in the context of tesamorelin, is the reduction of visceral adipose tissue (VAT). Visceral fat is deep-seated adipose tissue surrounding the internal organs, strongly associated with cardiovascular disease, insulin resistance, chronic inflammation, fatty liver disease and accelerated biological ageing. In pooled phase III studies involving HIV-positive individuals with abdominal obesity, Falutz et al. (2010) demonstrated that tesamorelin reduced visceral fat by approximately 15.4% over 26 weeks, whilst improving triglyceride levels and cholesterol ratios without a significant deterioration in glucose metabolism [3]. Long-term studies have shown that this reduction could persist for up to 52 weeks with continued therapy [4]. Reducing visceral fat is considered an important component of healthy ageing, as excess VAT promotes chronic inflammation and cardiometabolic disorders.
Tesamorelin may also support healthy ageing by influencing liver function and mitochondrial health. In randomised trials involving individuals with HIV-associated non-alcoholic fatty liver disease (NAFLD), Stanley et al. (2019) demonstrated that tesamorelin reduced hepatic fat by approximately 37% over 12 months [5]. Fourman et al. (2020) additionally noted an improvement in the expression of genes associated with oxidative phosphorylation, mitochondrial metabolism and energy production, whilst simultaneously reducing inflammatory pathways and fibrosis [6]. Oxidative phosphorylation is the process by which cells produce energy in the mitochondria. As mitochondrial dysfunction and chronic inflammation are strongly associated with ageing, these results suggest that tesamorelin may influence key metabolic pathways linked to longevity, going beyond mere fat reduction.
Another area of interest is the potential impact of tesamorelin on muscle quality, recovery, and physical fitness. Ageing is often associated with sarcopenia, a decline in muscle density, slower recovery, and reduced physical capacity. Adrian et al. (2019) demonstrated that tesamorelin improved both muscle density and muscle cross-sectional area in adults with HIV and excess abdominal fat [7]. Improved muscle quality and the preservation of lean body mass can support mobility, recovery ability, and resilience during ageing. GH and IGF-1 signalling are also involved in tissue repair, collagen synthesis, and cellular repair processes, which is why GH secretagogues are frequently investigated for their potential to support recovery and performance.
Tesamorelin has also shown potential impact on cognitive and neurological functions associated with healthy ageing. In a randomised, placebo-controlled study involving older adults with and without mild cognitive impairment, Baker et al. (2012) reported improvements in executive functions and selected aspects of memory, along with an increase in IGF-1 levels within the physiological range [8]. Further research by Friedman et al. (2013) suggested beneficial effects of tesamorelin on brain neurochemistry, including an increase in gamma-aminobutyric acid (GABA) levels and a reduction in markers associated with neuroinflammation [9]. These findings suggest that modulation of the GH–IGF-1 axis may influence cognitive ageing, neuronal signalling, and brain metabolism.
Tesamorelin may also support overall metabolic resilience and hormonal optimisation. Makimura et al. (2014) demonstrated that tesamorelin-induced IGF-1 increases were associated with improved mitochondrial phosphocreatine recovery and cellular energy metabolism in obese adults with growth hormone deficiency [10]. Other studies have also shown improvements in adiponectin levels, inflammatory markers, lipid profiles, and cardiovascular risk markers, along with a reduction in visceral fat [3,5,11]. Adiponectin is a hormone associated with improved insulin sensitivity and metabolic health. Collectively, these metabolic changes may support healthier ageing by improving energy utilisation, reducing inflammation, and increasing metabolic flexibility.
Despite promising results, tesamorelin is not officially approved as anti-ageing therapy or for longevity support, and most research has been conducted in individuals with HIV-associated lipodystrophy or metabolic diseases, rather than in healthy ageing populations. Furthermore, as tesamorelin increases GH and IGF-1 activity, appropriate monitoring remains important during therapy. Excessive GH or IGF-1 activity could theoretically increase the risk of oedema, joint pain, insulin resistance, or abnormal tissue growth in susceptible individuals [1,2]. Clinical studies generally indicate that tesamorelin is relatively well tolerated; however, routine monitoring of glucose and IGF-1 levels remains a standard recommendation.
In summary, current data suggest that tesamorelin may support healthy ageing by improving visceral fat metabolism, preserving lean muscle mass, supporting mitochondrial and liver function, enhancing regeneration, and potentially aiding cognitive health through the physiological activation of the GH–IGF-1 axis. Despite promising results, tesamorelin remains primarily a metabolic therapy for specific medical indications, rather than an established longevity treatment. Further long-term research in healthy ageing populations is still needed.
Disclaimer
The content is for educational and scientific information purposes only and should not be construed as medical advice, diagnosis, or therapeutic recommendation. Tesamorelin is an FDA-approved prescription medication for specific medical indications and has not been officially approved as an anti-aging or longevity therapy. Hormone therapies impacting growth hormone and IGF-1 pathways may carry risks and should only be undertaken under the supervision of a qualified healthcare professional with appropriate laboratory monitoring and individual medical assessment.
References
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548730/
- PubChem. (2025). Tesamorelin Compound Summary. National Centre for Biotechnology Information, National Library of Medicine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin
- Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicentre, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
- Falutz, J., Allas, S., Mamputu, J. C., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058
- Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Agyapong, G., Torriani, M., Chung, R. T., & Grinspoon, S. K. (2019). Effect of tesamorelin on non-alcoholic fatty liver disease in HIV-positive individuals: A randomised, double-blind, multicentre study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
- Fourman, L. T., Billingsley, J. M., Agyapong, G., Ho Sui, S. J., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Corey, K. E., Torriani, M., Kleiner, D. E., Hadigan, C. M., Stanley, T. L., Chung, R. T., & Grinspoon, S. K. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5(16), e140134. https://doi.org/10.1172/jci.insight.140134
- Adrian, S., Scherzinger, A., Sanyal, A., et al. (2019). Growth hormone-releasing hormone analogue tesamorelin reduces fat and increases muscle area in adults with HIV. The Journal of Frailty & Ageing, 8(3), 154–159. https://doi.org/10.14283/jfa.2018.45
- Baker, L. D., Barsness, S. M., Borson, S., et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: Results of a controlled study. Archives of Neurology, 69(11), 1420–1429. https://doi.org/10.1001/archneurol.2012.1970
- Friedman, S. D., Baker, L. D., Borson, S., et al. (2013). Effects of growth hormone-releasing hormone on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy ageing. JAMA Neurology, 70(7), 883–890. https://doi.org/10.1001/jamaneurol.2013.1425
- Makimura, H., Murphy, C. A., Feldpausch, M. N., & Grinspoon, S. K. (2014). Effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. The Journal of Clinical Endocrinology & Metabolism, 99(1), 338–343. https://doi.org/10.1210/jc.2013-3436
- Stanley, T. L., Falutz, J., Mamputu, J. C., Soulban, G., Potvin, D., & Grinspoon, S. K. (2011). Effect of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: Relationship with visceral adipose tissue reduction. AIDS, 25(10), 1281–1288. https://doi.org/10.1097/QAD.0b013e328347f3f1